Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo (Q40784483)

23 September 2017

Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo (English)

1 reference

23 September 2017

Morris A

1

1 reference

23 September 2017

Vetto JT

2

1 reference

23 September 2017

Ramstad T

3

1 reference

23 September 2017

Funatake CJ

4

1 reference

23 September 2017

Choolun E

5

1 reference

23 September 2017

Entwisle C

6

1 reference

23 September 2017

Weinberg AD

7

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Breast Cancer Research and Treatment

23 September 2017

1 reference

23 September 2017

67

1 reference

23 September 2017

1

1 reference

23 September 2017

71-80

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1010649303056

23 September 2017

0 references

cites work

Signals and signs for lymphocyte responses

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Pituitary-isografted mice are highly susceptible to MNU-induced mammary carcinogenesis irrespective of the level of alveolar differentiation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

1 reference

7 January 2021

Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Patterns of axillary lymph node metastasis in breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Monoclonal Antibodies Detect Occult Breast Carcinoma Metastases in the Bone Marrow of Patients with Early Stage Disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

The tumor necrosis factor ligand and receptor families.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010649303056

7 January 2021

Identifiers

DOI

10.1023/A:1010649303056

1 reference

Dimensions Publication ID

23 September 2017

0 references

1 reference